188 related articles for article (PubMed ID: 1646663)
21. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
[TBL] [Abstract][Full Text] [Related]
22. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus induces interstitial lung disease in allogeneic bone marrow transplant recipient rats independent of acute graft-versus-host response.
Stals FS; Steinhoff G; Wagenaar SS; van Breda Vriesman JP; Haverich A; Dormans P; Moeller F; Bruggeman CA
Lab Invest; 1996 Feb; 74(2):343-52. PubMed ID: 8780154
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
[TBL] [Abstract][Full Text] [Related]
25. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis.
Rolstad B; Benestad HB
Immunology; 1991 Sep; 74(1):86-93. PubMed ID: 1937576
[TBL] [Abstract][Full Text] [Related]
26. The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells.
Morecki S; Nabet C; Ackerstein A; Schlesinger M; Slavin S
Bone Marrow Transplant; 1991 Apr; 7(4):269-73. PubMed ID: 2070132
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
Walker CM; van Burik JA; De For TE; Weisdorf DJ
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
[TBL] [Abstract][Full Text] [Related]
28. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
29. [Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?].
Blot F; Mayaud C; Frachon I; Couderc LJ; Stern M; Friard S; Caubarrère I
Rev Pneumol Clin; 1995; 51(6):309-20. PubMed ID: 8746018
[TBL] [Abstract][Full Text] [Related]
30. Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy.
Wang JY; Chang YL; Lee LN; Chen JH; Tang JL; Yang PC; Lee YC
Ann Thorac Surg; 2004 Jul; 78(1):267-72. PubMed ID: 15223441
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
Reusser P; Riddell SR; Meyers JD; Greenberg PD
Blood; 1991 Sep; 78(5):1373-80. PubMed ID: 1652311
[TBL] [Abstract][Full Text] [Related]
34. Natural cytotoxic activity against cytomegalovirus-infected target cells following marrow transplantation.
Bowden RA; Day LM; Amos DE; Meyers JD
Transplantation; 1987 Oct; 44(4):504-8. PubMed ID: 2823422
[TBL] [Abstract][Full Text] [Related]
35. Increased cytotoxicity against cytomegalovirus-infected target cells by bronchoalveolar lavage cells from bone marrow transplant recipients with cytomegalovirus pneumonia.
Bowden RA; Dobbs S; Kopecky KJ; Crawford S; Meyers JD
J Infect Dis; 1988 Oct; 158(4):773-9. PubMed ID: 2844915
[TBL] [Abstract][Full Text] [Related]
36. Undetected viral infection in diffuse alveolar damage associated with bone marrow transplantation.
Barberà JA; Martín-Campos JM; Ribalta T; Carreras E; Liopart A; Sierra J; Rozman C; Rodríguez-Roisin R
Eur Respir J; 1996 Jun; 9(6):1195-200. PubMed ID: 8804937
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus (CMV) in the compromised host(s).
Betts RF; Hanshaw JB
Annu Rev Med; 1977; 28():103-10. PubMed ID: 193429
[TBL] [Abstract][Full Text] [Related]
38. Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantation.
de Rham C; Hadaya K; Bandelier C; Ferrari-Lacraz S; Villard J
Transpl Immunol; 2014 Sep; 31(3):157-64. PubMed ID: 25158213
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation.
Wingard JR; Chen DY; Burns WH; Fuller DJ; Braine HG; Yeager AM; Kaiser H; Burke PJ; Graham ML; Santos GW
Blood; 1988 May; 71(5):1432-7. PubMed ID: 2833959
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation.
Nagler A; Elishoov H; Kapelushnik Y; Breuer R; Or R; Engelhard D
Med Oncol; 1994; 11(3-4):127-32. PubMed ID: 7633832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
